$MLTX News

HC Wainwright & Co. Maintains Buy on MoonLake, Raises Price Target to $50

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study

MoonLake Immunotherapeutics Reports Topline Results From Phase 3 IZAR-1 Trial Showing Sonelokimab Met All Week 16 Endpoints In Biologic‑Naïve Psoriatic Arthritis Patients

MoonLake Q2 EPS $(0.84) Beats $(0.93) Estimate

MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data

Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $45 Price Target

MoonLake Immunotherapeutics' CFO Sells 39K Shares

Leerink Partners Maintains Outperform on MoonLake, Raises Price Target to $29

MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa

MoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label Expansion

How Investors May Respond To MoonLake Immunotherapeutics (MLTX) VELA Data And Upsized Follow-On Offering

MLTX Stock Extends Pullback After Biggest Rally In Over 6 Months Following Skin Disease Trial Data — A Look At The Latest Development

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

MoonLake Immunotherapeutics: Label Upside Drives The Next Leg Higher

MLTX Stock Clocks Best Day In Over 6 Months — What’s Driving The Investor Optimism?

MoonLake Immunotherapeutics Announces Proposed Public Offering

MoonLake Immunotherapeutics Announces Proposed Public Offering Of $150M Of Its Class A Ordinary Shares

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day - Slideshow